Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Gains from Investment Securities (2022 - 2025)

Oramed Pharmaceuticals' Gains from Investment Securities history spans 4 years, with the latest figure at $1.0 million for Q3 2025.

  • For Q3 2025, Gains from Investment Securities rose 13921.1% year-over-year to $1.0 million; the TTM value through Dec 2025 reached -$20.7 million, changed N/A, while the annual FY2025 figure was $1.7 million, 28.31% down from the prior year.
  • Gains from Investment Securities reached $1.0 million in Q3 2025 per ORMP's latest filing, up from $294000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $1.0 million in Q1 2025 to a low of -$16.2 million in Q4 2023.
  • Average Gains from Investment Securities over 4 years is -$1.3 million, with a median of $46900.0 recorded in 2023.
  • Peak YoY movement for Gains from Investment Securities: tumbled 9105.11% in 2023, then surged 38584.21% in 2025.
  • A 4-year view of Gains from Investment Securities shows it stood at -$176000.0 in 2022, then crashed by 9105.11% to -$16.2 million in 2023, then skyrocketed by 100.05% to $7300.0 in 2024, then skyrocketed by 13921.1% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Gains from Investment Securities are $1.0 million (Q3 2025), $294000.0 (Q2 2025), and $1.0 million (Q1 2025).